Sagimet Biosciences Reports Successful Phase 3 Results for Denifanstat in Moderate to Severe Acne and Initiates Phase 1 Trial for TVB-3567

Sagimet Biosciences (SGMT) announced positive Phase 3 trial results for denifanstat, an oral fatty acid synthase (FASN) inhibitor, in treating moderate to severe acne, with the drug meeting all primary and secondary endpoints related to lesion reduction and clinical assessments in a trial conducted by its partner Ascletis in China; denifanstat also demonstrated favorable tolerability. Sagimet has also initiated a Phase 1 trial in the U.S. for a second FASN inhibitor, TVB-3567, for acne, signaling a commitment to expanding its pipeline in this therapeutic area. Recent hedge fund activity shows mixed sentiment with some firms increasing positions while others significantly reduced theirs in the last quarter.

Analysis

Sagimet Biosciences (SGMT) reported highly positive Phase 3 clinical trial results for denifanstat, an oral fatty acid synthase (FASN) inhibitor, in treating moderate to severe acne vulgaris. The trial, conducted by partner Ascletis in China, met all primary and secondary endpoints, with denifanstat demonstrating statistically significant efficacy over placebo. Specifically, 33.2% of patients on denifanstat achieved treatment success (IGA score of 0 or 1 with at least a 2-point decrease) compared to 14.6% on placebo (p<0.0001). Total lesion count decreased by 57.4% with denifanstat versus 35.4% with placebo (p<0.0001), and inflammatory lesion count decreased by 63.5% versus 43.2% respectively (p<0.0001). Denifanstat was well-tolerated, with treatment-emergent adverse events comparable to placebo and no serious adverse events reported; dry skin (6.3% vs 2.9%) and dry eye (5.9% vs 3.8%) were the most notable TEAEs exceeding 5% incidence. These results validate FASN inhibition as a novel mechanism for acne, a market with significant unmet need and limited innovation. Sagimet is also advancing its own FASN inhibitor, TVB-3567, into a Phase 1 trial in the U.S. for acne, indicating a strategic focus on this therapeutic area. However, institutional sentiment appears mixed; while 33 investors added SGMT shares, 43 decreased positions. Notably, NEA Management Company and Citadel Advisors LLC significantly reduced their holdings by 2,000,275 shares (-100.0%) and 701,564 shares (-94.2%) respectively in Q1 2025, alongside substantial decreases from Point72 and Millennium Management. Conversely, Raymond James Financial Inc and Balyasny Asset Management L.P. initiated or significantly increased positions. The reliance on Ascletis for denifanstat's development in China and the geographical specificity of these trial results are points to consider for global applicability, alongside the long-term safety profile of this novel drug class.

Key Decisions for Investors

• Evaluate the positive Phase 3 data for denifanstat as a significant de-risking event for Sagimet's FASN inhibitor platform, particularly validating the mechanism of action for acne.
• Closely monitor the progress of Sagimet's directly controlled Phase 1 trial for TVB-3567 in the U.S., as this represents a key catalyst for market access beyond China.
• Consider the implications of the mixed institutional ownership changes, particularly the large stake reductions by prominent funds, and investigate potential underlying reasons despite positive clinical news.
• Assess the risk associated with the current positive data being China-specific and its potential translation to broader regulatory approvals and market acceptance in regions like the U.S. and Europe.